• OFID 2018:5 (Suppl 1) • Poster Abstracts (CAV), cefepime (CEF), ciprofloxacin (CIP), colistin (CL), meropenem (MR), ceftolozane/tazobactam (C/T), tigecycline (TG), and trimethoprim/sulfamethoxazole (T/S).
Background. Fungal infections are a critical cause of morbidity and mortality in burn patients. In addition to debridement and systemic antifungal therapy, various topical adjuncts have been used, and topical burn care is a key component of infection prevention and treatment. Cerium nitrate (CN) has been used in combination with silver sulfadiazine (SS) in burn care. Previous studies showed that CN had bacteriostatic activity, and suggested anti-biofilm activity against Candida biofilms. In this study, we evaluated the in vitro activity of CN against fungal isolates associated with combat-related injuries.
Methods. The efficacy of CN was evaluated against 14 mold (three Aspergillus spp., two Fusarium spp., five different mucormycetes, two Bipolaris spp., one Alternaria spp., one Exophiala spp.) and 21 Candida spp. isolates collected as part of the Trauma Infectious Disease Outcomes Study. Fungicidal activity of various concentrations of CN (2.2%, 1%, 0.5% and 0.2%) was determined using an established time-kill assay. Standard conidia/cell suspensions were prepared according to Clinical and Laboratory Standards Institute guidelines and then exposed to the CN solutions for 24 hours. At different times (0, 5, 15, 30 minutes, 1, 1.5, 3, 6, 12 , and 24 hours) aliquots were plated and incubated at 35ºC. Colony forming unit (CFU) counts were determined after 24 hours incubation or after an appropriate time for slow growing molds.
Results. All mold isolates had persistent growth at 24 hours with most having no significant change in colony counts over the 24-hour period. The only exception was Mucor circinelloides, which appeared to have a time-dependent reduction in CFUs at 24 hours for all CN concentrations. Exophiala did not grow as well in CN solutions compared with the control (mean 65 vs. 28.2 CFUs with a difference of mean 37.4 CFUs, P = 0.0001), but this was not time or concentration dependent. All yeast species showed a time-dependent killing after 6-12 hours.
Conclusion. CN demonstrated time-dependent killing of the yeasts. However, very little activity was observed against the tested molds. Since CN is often used in combination with SS there might be a synergistic effect against molds. Further research will evaluate higher concentrations of CN and its toxicity for cells and tissue.
Disclosures. All authors: No reported disclosures. Background. Omadacycline is a novel aminomethylcycline that recently completed Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia (CABP). This study evaluated the activity of omadacycline against a broad collection of recent (2016) clinical isolates with molecularly characterized tetracycline resistance mechanisms.
Omadacycline In Vitro Activity Against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms
Methods. A total of 177 Gram-positive and -negative clinical isolates were identified as carrying acquired tetracycline resistance genes and were included in this study. Isolates were previously subjected to next-generation sequencing followed by screening of known tetracycline resistance mechanisms. Susceptibility testing and interpretation were performed according to CLSI methods.
Results. Omadacycline demonstrated MIC 50 values of 0.06-0.12 µg/mL against Gram-positive isolates carrying tet genes. Similar MIC results (0.06-0.12 µg/mL) were obtained against Gram-positive organisms carrying tet(K), tet(L)/tet(M) or tet(M). Omadacycline (MIC 50/90 , 0.12/0.25 µg/mL) and tigecycline (MIC 50/90 , 0.06/0.25 µg/mL) showed similar MIC results when tested against Staphylococcus aureus carrying tet(K). While tetracycline was less active (0.0-78.6% susceptible) against Tet(K)-producing S. aureus, doxycycline (MIC 50/90 , 0.5/0.5 µg/mL; 100.0% susceptible) was active in vitro. Omadacycline (MIC 90 , 0.25-2 µg/mL) and tigecycline (MIC 90 , 0.12-1 µg/mL) showed potent MIC results against Gram-positive isolates carrying tet(L) and/or tet(M). Tetracycline and doxycycline had MIC 90 values of ≥8 µg/mL. Omadacycline (MIC 90 4-32 µg/mL) and tigecycline (MIC 90 0.5-2 µg/mL) were active against Gramnegative isolates harboring tet(A), tet(B) or tet(D) or a combination of tet. Tetracycline (MIC 50/90 , >16/>16 µg/mL) and doxycycline (MIC 50/90 , >8/>8 µg/mL) had elevated MIC 50 and MIC 90 results against these isolates.
Conclusion. Results presented here indicate that omadacycline is not adversely affected by tet genes present in contemporary Gram-positive and -negative clinical isolates, a characteristic that differs from the legacy tetracycline agents.
